Lurbinectedin
- Generic Name
- Lurbinectedin
- Brand Names
- Zepzelca, 赞必佳
- Drug Type
- Small Molecule
- Chemical Formula
- C41H44N4O10S
- CAS Number
- 497871-47-3
- Unique Ingredient Identifier
- 2CN60TN6ZS
- Background
Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin (trabectedin), an anticancer agent found in extracts of the tunicate Ecteinascid...
- Indication
Lurbinectedin is indicated for the treatment of adult patients with metastatic small-cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
- Associated Conditions
- Metastatic Lung Small Cell Carcinoma
- Associated Therapies
- -
LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- ERLINDA M GORDON
- Target Recruit Count
- 40
- Registration Number
- NCT05876715
- Locations
- 🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 280
- Registration Number
- NCT05800587
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 509
- Registration Number
- NCT05740566
- Locations
- 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT05734066
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Stanford Children's Health, Palo Alto, California, United States
🇺🇸Corewell Health, Grand Rapids, Michigan, United States
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT05636111
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study of Trilaciclib and Lurbinectidin
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05578326
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
- Conditions
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-01-06
- Target Recruit Count
- 312
- Registration Number
- NCT05285033
- Locations
- 🇫🇷
Villefranche-Sur-Saône - CH, Villefranche-sur-Saône, France
🇫🇷Institut Curie, Paris, France
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Emory University
- Target Recruit Count
- 22
- Registration Number
- NCT05244239
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 705
- Registration Number
- NCT05153239
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇱Clinical Research Chile SpA, Valdivia, Los Ríos, Chile
🇨🇭University Hospital Basel, Basel, Switzerland
Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201)
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT05126433
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸Bon Secours Hematology and Oncology, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.